Abstract: This invention relates to new propanolamine derivatives or salts thereof represented by the following formula [I]:
Wherein each symbol is as defined in the specification or salts thereof which have gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence and anti-pollakiuria activities, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the prevention and/or treatment diseases indicated in the specification to a human being or an animal.
Abstract: In accordance with the present invention, a novel class of substituted pyridine compounds (optionally containing ether, ester, amide, ketone or thioether substitutions) that promote the release of ligands involved in neurotransmission have been discovered. In a particular aspect compounds of the present invention are capable of modulating acetylcholine receptors. The compounds of the present invention are capable of modulating acetylcholine receptors. Invention compounds may act as agonists, partial agonists, antagonists or allosteric modulators of acetylcholine receptors.
Type:
Grant
Filed:
December 22, 1997
Date of Patent:
October 14, 2003
Assignee:
Merck & Co., Inc.
Inventors:
Jean-Michel Vernier, Nicholas D. P. Cosford, Ian A. McDonald
Abstract: &agr;- and &bgr;-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.
Type:
Application
Filed:
May 30, 2002
Publication date:
October 9, 2003
Applicant:
G.D. Searle & Co.
Inventors:
Michael L. Vazquez, Richard A. Mueller, John J. Talley, Daniel P. Getman, Gary A. DeCrescenzo, John N. Freskos, Deborah E. Bertenshaw, Robert M. Heintz
Abstract: Compounds of formula (I) or (II):
or salts therefor are used as phytopathogenic fungicides wherein the various radicals and substitutents are as defined in the description. Pesticidal compositions contain these compounds together with an agriculturally acceptable diluent or carrier. The compounds and compositions are applied in methods for combating pests.
Type:
Grant
Filed:
July 22, 2002
Date of Patent:
October 7, 2003
Assignee:
Bayer Cropscience GmbH
Inventors:
Tracey Cooke, Tennyson Ekwuru, David Hardy, Peter Millward, Brian Moloney, Andrew Pettinger, Peter Stanley Thomas, Richard Michael Turner
Abstract: Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines and arylthioalkylamines, including pyridyloxyl-alkylamines, phenoxyalkylamines, pyridylthiolalkylamines and phenylthio-alkylamines. Exemplary compounds include (2-(5-bromo(3-pyridylthio))-ethyl)methylamine, (2-(5-bromo(3-pyridylthio))isopropyl)methylamine, (2-(5-bromo(3-pyridylthio))propyl)methylamine, (3-(5-bromo(3-pyridylthio))-propyl)methylamine, 3-((3S)-3-pyrrolidinyloxy)pyridine, 3-(4-piperidinyloxy)pyridine, 3-(1-methyl-4-piperidinyloxy)pyridine, (3-benzo[3,4-d]1,3-dioxolan-5-yloxypropyl)methylamine, and methyl(3-tricyclo[7.3.1.0<5,13>]tridec-2-yloxypropyl)amine.
Type:
Grant
Filed:
August 13, 2001
Date of Patent:
September 30, 2003
Assignee:
Targacept, Inc.
Inventors:
Gary Maurice Dull, Erin E. Reich, Jared Miller Wagner, Balwinder Singh Bhatti, Michael B. Consilvio
Abstract: Compounds of formula (I) and salts thereof as phytopathogenic fungicides wherein A1 is substituted 2-pyridyl; A2 is optionally substituted phenyl; L is —(C═O)—, —SO2— or —(C═S)—; R1 is hydrogen, optionally substituted alkyl or acyl; and R2 is hydrogen or optionally substituted alkyl are useful phytopathogenic fungicides.
Type:
Application
Filed:
November 25, 2002
Publication date:
September 11, 2003
Applicant:
Aventis CropScience UK Limited
Inventors:
Brian Anthony Moloney, David Hardy, Elizabeth Anne Saville-Stones
Abstract: Organic or inorganic salts of compounds of general formula: A—X1—N(O)z for use as medicaments having anti-inflammatory, analgesic and antithrombotic activity, wherein A is R(COXu)t wherein t is 0 or 1; u is 0 or 1 and X is O, NH, NR1c wherein R1c us a C1-C10 alkyl and R is, for example, (Ia) wherein R1 is acetoxy, preferably in ortho position with respect to —CO— and R2 is hydrogen or acetylsalicylsalicylic acid derivatives; and X1 is the formula (B), Y being a ring containing at least one salified nitrogen atom.
Abstract: A class of imidazolyl compounds is described for use in treating inflammation. Compounds of particular interest are defined by Formula V:
and pharmaceutically-acceptable salts thereof.
Type:
Grant
Filed:
December 5, 2001
Date of Patent:
September 2, 2003
Assignee:
G. D. Searle & Co.
Inventors:
Ish K. Khanna, Richard M. Weier, Paul W. Collins, Yi Yu, Xiangdong Xu, Richard A. Partis, Francis J. Koszyk, Renee M. Huff
Abstract: Compounds of the invention are useful in inhibiting thrombin and treating blood coagulation and cardiovascular disorders and have the following structure:
wherein
R3 is hydrogen or halogen, and u is N or CH.
Type:
Grant
Filed:
February 8, 2002
Date of Patent:
August 26, 2003
Assignee:
Merck & Co., Inc.
Inventors:
James C. Barrow, Craig Coburn, Harold G. Selnick, Phung L. Ngo
Abstract: Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes are useful for inducing or promoting apotosis and for arresting uncontrolled neoplastic cell proliferation, and are specifically useful in the arresting and treatment of neoplasias, including precancerous and cancerous lesions.
Type:
Grant
Filed:
July 26, 2002
Date of Patent:
August 26, 2003
Assignees:
Cell Pathways, Inc., University of Arizona
Inventors:
Gerhard J. Sperl, Paul Gross, Klaus Brendel, Gary A. Piazza, Rifat Pamukcu
Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
Type:
Grant
Filed:
June 14, 1999
Date of Patent:
August 19, 2003
Assignee:
Vertex Pharmaceuticals Incorporated
Inventors:
Guy W. Bemis, Francesco Gerald Salituro, John Patrick Duffy, John E. Cochran, Edmund Martin Harrington, Mark A. Murko, Keith P. Wilson, Michael Su, Vincent P. Galullo
Abstract: Substituted anthranilic acids of the formula I
their use as a medicament or diagnostic, and medicament comprising them, and a pharmaceutical combination preparation containing a sodium/hydrogen exchange (NHE) blocker.
Abstract: The present invention relates to a method of treating alcoholism or alcohol dependence in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with an opioid antagonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and an opioid antagonist.
Abstract: One aspect of the present invention relates to methods for the transition-metal-catalyzed asymmetric 1,4-addition of a nucleophile, e.g., hydride, to cyclic and acyclic enoates and enones. In certain embodiments of the methods of the present invention, the transition metal catalyst consists essentially of copper and an asymmetric bidentate bisphosphine ligand.
Type:
Application
Filed:
October 15, 2002
Publication date:
July 3, 2003
Inventors:
Stephen L. Buchwald, Daniel H. Appella, Yasunori Moritani, Ryo Shintani, Valdas Jurkauskas
Abstract: A compound of the formula (I), wherein R1 is hydrogen, halogen, carbymoyl, cyano, formuly, or lower alkyl optionally substituted with halogen, amino or a protected amino, R2 is hydrogen, halogen, cyano or lower alkoxy, R3 is phenyl or pyridyl, each of which is substituted with lower alkoxy, and R4 is lower alkoxy; provided that either R1 or R2 is hydrogen, then the other is other than hydrogen, or its salts, which are useful as a medicament.
Abstract: Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.
Type:
Application
Filed:
September 26, 2002
Publication date:
June 5, 2003
Inventors:
Kimberley Q. Cameron, Hua Z. Ke, Bruce A. Lefker, Robert L. Rosati, David D. Thompson
Abstract: Couplers for hair coloring compositions for oxidative dyeing of hair are compounds of the formula (1):
wherein X is selected from halogen and R2SO4; R3 is selected from C1 to C2 alkyl or hydroxyethyl; R2 is selected from C1 to C22 alkyl and C1 to C22 mono and dihydroxyalkyl; and R is selected from of C1 to C16 alkyl, C1 to C10 hydroxyalkyl, C1 to C6 alkoxyalkyl and benzyl.
Abstract: Compounds of Formula I are antagonists of VLA-4 and/or &agr;4&bgr;7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.
Type:
Application
Filed:
May 21, 2001
Publication date:
May 15, 2003
Inventors:
William K. Hagmann, Stephen E. DeLaszlo, Theodore Kamenecka, Malcolm MacCoss
Abstract: This invention is in the field of antiinflammatory pharmaceutical agents and specifically relates to compounds, compositions and methods for treating disorders mediated by cyclooxygenase-2 or 5-lipoxygenase, such as inflammation.
Type:
Application
Filed:
July 8, 2002
Publication date:
April 17, 2003
Applicant:
Pharmacia Corporation
Inventors:
John J. Talley, James A. Sikorski, Matthew J. Graneto, Bryan H. Norman, Balekudru Devadas, Hwang-Fun Lu
Abstract: The present invention is a process for the preparation of a compound of Formula (IA) or a pharmaceutically acceptable salt thereof:
that includes preparing a diamide of Formula (II) or a pharmaceutically acceptable salt thereof:
Abstract: The present invention relates to processes for the preparation of any of the intermediate 1,3-substituted indenes of the formulae (Ia), (Ib) and (Ic) or a mixture thereof: 1
Abstract: Propanolamine derivatives represented by the following formula (I):
These derivatives may be &bgr;3 agonists and exert sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic and anti-urinary incontinence and anti-pollakiuria activities. Pharmaceutical compositions containing such propanolamine derivatives, methods for the prevention and/or treatment diseases using these propanolamine derivatives, and processes for their preparation are also described.
Abstract: A process is provided for preparing a compound having the formula
comprising:
(a) reacting a compound having the formula
with an isocyanate having the formula R1NCO to produce a compound having the formula
(b) optionally hydrolyzing the compound of formula (III) to form an amide having the formula
(c) reacting the compound of formula (III) or the amide of formula (IV) with a compound having the formula
in the presence of a strong base to produce a compound having the formula
and
(d) cyclizing the compound of formula (VI) to obtain the compound of formula (I), wherein R is H or Cl; M is selected from the group consisting of Li, Na, K, MgX, ZnRA, and Al(RA)2; RA is alkyl; X is halo; R1 is selected from the group consisting of alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; and L is a leaving group.
Type:
Grant
Filed:
April 17, 2001
Date of Patent:
December 10, 2002
Assignee:
Schering Corporation
Inventors:
Marc Poirier, Yee-Shing Wong, George G. Wu
Abstract: The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N-phenyl-N-fused-benzyl aminoalcohols.
Type:
Application
Filed:
November 14, 2001
Publication date:
December 5, 2002
Inventors:
James A. Sikorski, Richard C. Durley, Doborah A. Mischke, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Margaret L. Grapperhaus, Brian S. Hickory, Mark A. Massa, Monica B. Norton, William F. Vernier, Barry L. Parnas, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
Abstract: A method for producing an aromatic primary amine, characterized by hydrogenating an aromatic nitrile at a low partial pressure of hydrogen in a heterogeneous system comprising a non-reductive polar solvent and a nickel-immobilized catalyst suspended therein was proposed. By such method, an aromatic primary amine which is industrially useful as a medicine, agricultural chemical, dye surfactant, chemical agent, etc. can be produced in a high yield.
Abstract: 4-Substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones having the Formula (I):
wherein R1, R2, R3, R4, R5, A and W are as defined in the specification which compounds relaxes smooth muscles.
Type:
Grant
Filed:
March 12, 2002
Date of Patent:
October 8, 2002
Assignee:
American Home Products
Inventors:
John A. Butera, Joseph R. Lennox, Douglas J. Jenkins
Abstract: Compounds useful as potassium channel inhibitors and especially useful for the treatment of cardiac arrhythmias and cell proliferative disorders are described.
Type:
Grant
Filed:
December 21, 2000
Date of Patent:
October 1, 2002
Assignee:
Icagen, Inc.
Inventors:
Michael Gross, Serge Beaudoin, Aimee D. Reed
Abstract: The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N-phenyl-N-heteroaralkyl aminoalcohols.
Type:
Grant
Filed:
November 23, 2001
Date of Patent:
October 1, 2002
Assignee:
G.D. Searle & Co.
Inventors:
James A. Sikorski, Richard C. Durley, Deborah A. Mischke, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Margaret L. Grapperhaus, Brian S. Hickory, Mark A. Massa, Monica B. Norton, William F. Vernier, Barry L. Parnas, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
Abstract: Squaric acid derivatives of formula (1) are described:
wherein
R1 is a group Ar1Ar2Alk- in which
Ar1 is an optionally substituted aromatic or heteroaromatic group;
Ar2 is an optionally substituted phenylene or nitrogen-containing six-membered heteroarylene group; and Alk is a chain
—CH2—CH(R)—, —CH═C(R)—,
in which R is a carboxylic acid (—CO2H) or a derivative or biostere thereof;
R2 is a hydrogen atom or a C1-6 alkyl group;
L1 is a covalent bond or a linker atom or group;
n is zero or the integer 1;
Alk1 is an optionally substituted aliphatic chain;
R3 is a hydrogen atom or an optionally substituted heteroaliphatic, cycloaliphatic, heterocycloaliphatic, polycycloaliphatic, heteropolycycloaliphatic, aromatic or heteroaromatic group: and the salts, solvates, hydrates and N-oxides thereof.
Type:
Grant
Filed:
December 21, 2000
Date of Patent:
September 24, 2002
Assignee:
Celltech R&D Limited
Inventors:
Barry John Langham, Rikki Peter Alexander, John Clifford Head, Janeen Marsha Linsley, John Robert Porter, Sarah Catherine Archibald, Graham John Warrellow
Abstract: Amides of the general formula I
and their tautomeric and isomeric forms, possible enantiomeric and diastereomeric forms, as well as possible physiologically tolerable salts, in which the variables have the following meanings:
R1 [sic] can be C1-C6-alkyl, phenyl, naphthyl, quinolyl, pyridyl, pyrimidyl, pyridazyl, quinazolyl and quinoxalyl, where the rings can additionally be substituted by up to 2 radicals R4 [sic], and
R2 [sic] is —(CH2)m—R8 [sic], where R8 [sic] can be phenyl, cyclohexyl- or indolyl and m=1 to 6, and
X is a bond, —CH2—, —CH2CH2—, —CH═CH—, —C≡C—, —CONH—, —SO2NH— [sic], and and [sic]
R1—X [sic] together are also
and
R3 [sic] is hydrogen and CO—NR6R7 [sic],
R4 [sic] is hydrogen, C1-C4-alkyl [sic], which is branched an
Abstract: Tertiary amines of the formula
wherein
A1, A2, A3, A4, M, p, T and Q are as defined herein, and acid addition salts thereof, have antimycotic and cholesterol-lowering activity.
Abstract: The invention concerns LTA4 hydrolase inhibiting compositions of formula (1) as set forth below. It also concerns their therapeutic, in particular anti-inflammatory, applications.
Type:
Grant
Filed:
June 11, 2001
Date of Patent:
August 20, 2002
Assignees:
Bioprojet, Institut National de la Sante et de la Recherche Medicale
(Inserm)
Abstract: The compounds of this invention comprise 2-10 ligands covalently connected, each of the ligands being capable of binding to a ligand binding site in a Na+ channel, thereby modulating the biological activities thereof.
Type:
Grant
Filed:
December 8, 1999
Date of Patent:
July 16, 2002
Assignee:
Advanced Medicine, Inc.
Inventors:
Daniel Marquess, Seok-Ki Choi, David T. Beattie, John H. Griffin, Scott Armstrong, Timothy J. Church, Thomas E. Jenkins
Abstract: The present invention relates to compounds of formula I,
and to their pharmaceutically acceptable salts. Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.
Abstract: &agr;-Unsaturated amines of the formula:
wherein X1 and X2 are such that one is an electron-attracting group with the other being a hydrogen atom or an electron-attracting group; R1 is a group attached through a nitrogen atom; R2 is a hydrogen atom or a group attached through a carbon, nitrogen or oxygen atom; n is an integer equal to 0, 1 or 2; A is a heterocyclic group or a cyclic hydrocarbon group, and salts thereof and their agrochemical use as insecticidal and/or miticidal agents are described.
Abstract: Disclosed are multibinding compounds which inhibit cyclooxygenase-2 (COX-2), an enzyme which catalyzes the first committed step in the biosynthesis of prostaglandins. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is a moiety capable of binding to COX-2. The multibinding compounds of this invention are useful in the treatment inflammation, pain, fever and the like.
Type:
Grant
Filed:
June 7, 1999
Date of Patent:
May 28, 2002
Assignee:
Advanced Medicine, Inc.
Inventors:
J. Kevin Judice, Deborah L. Higgins, John H. Griffin
Abstract: The present invention includes array of new chiral ligands that are optically active or racemic. These ligands are bidentate, tridentate, tetradentate or pentadentate ligands which include P-P, P-N, N-N, mixed P-N, Schiff base or carbene sites. The present invention further includes a catalyst prepared by a process, which includes contacting a transition metal salt, or a complex thereof, and a ligand according to the present invention. The present invention still further includes a process for preparation of an asymmetric compound. In this process, a substrate capable of forming an asymmetric product by an asymmetric reaction and a catalyst according to the present invention are contacted to produce an asymmetric product. Transition metal complexes with these ligands are effective catalysts for asymmetric reactions.
Abstract: 2-Sulfamoylbenzoic acid derivatives of general formula (I):
which have both an antagonistic effect on the leukotriene D4 receptor and an antagonistic effect on the thromboxane A2 receptor and salts thereof, pharmaceuticals, anti-allergic agents and leukotriene-thromboxane A2 antagonistic agents containing them as an active ingredient.
Type:
Grant
Filed:
April 27, 2001
Date of Patent:
April 23, 2002
Assignee:
Kaken Pharmaceutical Co., Ltd.
Inventors:
Yoshihiro Ichikawa, Tokiko Nishida, Jun Nakano, Mitsuru Watanuki, Masahiro Suda, Tsutomu Nakamura
Abstract:
The invention concerns a method for preparing compounds of formula (I) wherein R represents a hydrogen atom or an allyl radical containing up to 8 carbon atoms, characterised in that it consists in subjecting a compound of formula (II) wherein alc represents the residue of an alkyl radical containing up to 4 carbon atoms to the action of a compound of formula (III): RCONH2, wherein R retains its previous meaning, to obtain the compound of formula (IV) wherein R retains its previous meaning which is subjected to cyclization to obtain the desired product of formula (I).
Type:
Grant
Filed:
January 26, 2001
Date of Patent:
March 5, 2002
Assignee:
Aventis Pharma S.A.
Inventors:
Raphael Bouchet, Jacques Lagouardat, Jacques Scholl
Abstract: The invention relates to polycyclic aryl and heteroaryl substituted benzene compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.
Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for stimulating the growth of neurites in nerve cells. The compounds and the compositions and methods that utilize them can be used, either alone or in conjunction with a neurotrophic factor, such as nerve growth factor, to promote repair of neuronal damage caused by disease or physical trauma.
Type:
Application
Filed:
June 27, 2001
Publication date:
January 31, 2002
Applicant:
VERTEX PHARMACEUTICALS INCORPORATED
Inventors:
Patricia McCaffrey, Perry M. Novak, Michael Mullican
Abstract: The present invention relates to quinolinium- and pyridinium-based fluorescent dyes. The dyes are useful for staining proteins in solution, in gels and on solid supports. The dyes of the invention exhibit higher fluorescence emission than known compounds when bound to proteins and also exhibit improved contrast of fluorescence intensity between their protein-bound and unbound states.
Type:
Grant
Filed:
October 5, 1999
Date of Patent:
January 1, 2002
Assignee:
Oxford Glycosciences (UK) Ltd.
Inventors:
Mark William Pennington, David Ian Scopes, Michael Glen Orchard
Abstract: Novel compounds having the formula:
wherein the constituent variables are defined herein. The compounds are constructed to include a central aromatic, aliphatic, or heterocyclic ring system. Attached to the central ring system are two linear groups having nitrogenous moieties that are derivatized with chemical functional groups. The ring system can include further nitrogenous moieties, either as ring atoms or on pendant groups attached to the ring, that may also be derivatized with chemical functional groups. The totality of the chemical functional groups imparts certain conformational and other properties to the these compounds. In accordance with certain embodiments of the invention, libraries of such compounds are prepared utilizing permutations and combinations of the chemical functional groups and the nitrogenous moieties to build complexity into the libraries.
Abstract: The invention relates to novel pyridyl derivatives, their use as medicaments, pharmaceutical formulations containing them and methods for their preparation.
Type:
Grant
Filed:
May 11, 1998
Date of Patent:
October 9, 2001
Assignee:
AstraZeneca AB
Inventors:
David Cheshire, David Cladingboel, Simon Hirst, Carol Manners, Michael Stocks
Abstract: Compounds of the general formula (1)
are described wherein W is a ═N—, and Z and L are described in the specifications. These compounds are phosphodiesterase type IV inhibitors and are useful in the prophylaxis and treatment of diseases such as asthma where an unwanted inflammatory response or muscular spasm is present.
Type:
Grant
Filed:
March 26, 1998
Date of Patent:
October 2, 2001
Assignee:
Celltech Therapeutics Limited
Inventors:
John Clifford Head, Graham John Warrellow, Rikki Peter Alexander
Abstract: This invention provides compounds of Formula I having the structure 1
Type:
Application
Filed:
January 26, 2001
Publication date:
August 30, 2001
Inventors:
John A. Butera, Craig E. Caufield, Russell F. Graceffa, Alexander Greenfield, Eric G. Gundersen, Lisa M. Havran, Alan H. Katz, Joseph R. Lennox, Scott C. Mayer, Robert E. McDevitt